Precision tremor measurement for ET clinical trials
Essential tremor affects an estimated 7 million people in the US, yet clinical trial endpoints remain limited to subjective rating scales. NeuroQuantix captures tremor frequency, amplitude, and velocity with ICC reliability of 0.97 — enabling trials with dramatically smaller enrollment.
The ET Measurement Challenge
TETRAS and FTM rating scales rely on clinician observation of tremor severity on 0-4 ordinal scales. This introduces inter-rater variability (ICC 0.74-0.85), requires large sample sizes, and cannot capture the frequency-amplitude-velocity relationships that define tremor pathophysiology. For novel therapeutics — particularly those targeting specific tremor frequencies — ordinal scales may be unable to detect the treatment effect.
Clinical Applications
Published Evidence
Evidence from peer-reviewed publications supporting digital kinematic endpoints for essential tremor assessment.
Velocity Spectral Peak
The most sensitive single metric for ET tremor quantification. Captures tremor frequency and amplitude in a single continuous measure with ICC = 0.97.
Haubenberger D, et al. Movement Disorders, 2011. DOI: 10.1002/mds.23808
Frequency-Amplitude Decomposition
Spectral analysis of pen velocity separates tremor components by frequency, enabling discrimination of ET (4-12 Hz) from enhanced physiological tremor.
Haubenberger D, et al. Movement Disorders, 2011
Pharmacological Sensitivity
Published data demonstrates that digitized tremor metrics detect propranolol response with effect sizes exceeding clinical rating scale changes.
Published literature consensus
Statistical Power Advantage
Higher measurement precision translates directly into smaller enrollment requirements. See the full interactive power curve comparison on our product page.
View Power VisualizationReady to discuss essential tremor endpoints?
Schedule a consultation to explore how precision digital endpoints can strengthen your essential tremor clinical program.